Introduction {#S1}
============

Ovarian cancer is a complex disease that remains difficult to diagnose at early stages and hence is difficult to treat ([@R4], [@R8], [@R9]). Epithelial ovarian cancers are subdivided into four major categories based on histological criteria and resemblance to epithelial components of the normal female reproductive tract ([@R9]). Approximately 70% of ovarian carcinomas are categorized as serous tumors because their histoarchitecture recapitulates the epithelium lining the human fallopian tube. Other categories include endometrioid, mucinous and clear cell subtypes ([@R4], [@R9]). Ovarian carcinomas are also classified as either low-grade or high-grade tumors. Clinically, low and high-grade ovarian cancer behave very differently, with low-grade cancers being more resistant to cytotoxic chemotherapy ([@R9]). Whereas low-grade tumors frequently exhibit alterations (mutations, deletions or amplifications) of genes in the *Kras* and *Pten/PI3K* pathways, high-grade tumors are associated frequently with mutations (or deletions) in the tumor repressor protein (*Trp53; p53*) gene ([@R9]) and may be derived from fimbrial epithleial cells of the distal Fallopian tube ([@R34], [@R42]) as well as from OSE cells ([@R3]). High-grade tumors may also exhibit amplification of *PIK3CA* (Astanehe A, Arenillas D *et al*., 2008, [@R51]) suggesting a link between PTEN and p53. Recent gene profiling and sequencing databases have identified mRNAs and microRNAs relatively over-expressed or under-expressed in various ovarian cancer subtypes ([@R4], [@R15], [@R18], [@R36], [@R37], [@R48]). However, our understanding this complex disease remains limited and continues to evolve as new information on the potential sites of origin and molecular pathways involved is obtained ([@R3], [@R16], [@R33], [@R42]).

To help understand the etiology of human ovarian cancer, several mouse models of this disease have been devised in recent years using novel, pioneering strategies. Oncogenes introduced into dispersed *Trp53* null ovarian cells using *in vitro* and *in vivo* approaches and avian retroviral receptors generated epithelial cell tumors ([@R47]). Other investigators have injected adenoviral vectors expressing Cre recombinase under the ovarian bursa to generate *Trp53^fl/fl^;Rb^fl/fl^* ([@R24]), *Pten^fl/fl^; LSL-Kras^G12D^* ([@R19]) and *Pten^fl/fl^;Apc^fl/fl^* ([@R62]) mutations, characterized as poorly differentiated carcinomas, endometrioid-like adenocarcinomas, endometrioid adenocarcinomas, respectively. Although the adenoviral injection approach has been a major breakthrough, it depends on a highly technical intervention that can deliver the vectors to bursal and/or oviductal cells in addition to the OSE, thereby obscuring the identity of the actual transformed cell type(s) ([@R10]). The anti-Mullerian hormone receptor (AMHR2) is expressed in multiple cells types, including Mullerian-derived ovarian surface epithelial (OSE) cells, stromal cells of the oviduct and uterus as well as ovarian granulosa cells ([@R21], [@R30], [@R64]). When the *Amhr2* promoter was used to drive expression of the SV40 T antigen, ovarian carcinomas developed with \~50% penetrance ([@R11]) verifying expression of *Amhr2-Cre* in OSE cells. More recently, when the *Amhr2-Cre* mice were used to disrupt the *Brca1* and *p53* genes ([@R64]), uterine leiomyosarcomas developed rapidly indicating that uterine *Amhr2-Cre* expressing smooth muscle cells are acutely sensitive to these particular mutations. Importantly, activation of the PI3K pathway by loss of *Pten* (*Pten^fl/fl^;Amhr2Cre* mice)([@R22], [@R40]) or over-expression of PI3K (*Pik3ca;Amhr2Cre* mice)([@R43]) or activation of the KRAS pathway by expression of stable mutant KRAS^G12D^(*Kras^G12D^;Amhr2Cre* mice)([@R22]) alone does not lead to ovarian cancer but can enhance OSE cell proliferation and metaplasia ([@R43]).

Recent studies from our laboratory have shown that activation of the RAS, MEK1, and ERK1/2 pathway directs specific cell fate decisions of ovarian granulosa cells in growing and preovulatory follicles as well as in cells that comprise the ovarian surface epithelium ([@R22], [@R23]). In preovulatory follicles activation of RAS and ERK1/2 by the LH surge is essential for ovulation and terminal differentiation of granulosa cells ([@R22]). Conversely, premature expression of a mutant stable KRAS (KRAS^G12D^) in granulosa cells of the *Kras^G12D^;Amhr2Cre* mice completely derailed early follicle development ([@R21]). Granulosa cells ceased dividing, failed to undergo apoptosis and did not differentiate. Because *Kras^G12D^* mutant granulosa cells expressed high levels of the tumor suppressor PTEN, we further disrupted the *Pten* gene in the *Kras^G12D^;Amhr2Cre* mouse strain. Surprisingly, the fate of granulosa cells in the abnormal follicles was not markedly altered in the *Kras^G12D^; Pten;Amhr2Cre* double mutant mice. However, the ovarian surface epithelial (OSE) cells developed into low-grade serous papillary adenocarcinomas (as classified by expert mouse and human pathologists) with 100% penetrance and died within 4-6 months of age due to tumor volume ([@R22]). Therefore, the *Pten^fl/fl^;Kras^G12D^;Amhr2-Cre* mice provide the first evidence that granulosa cells are highly resistant to many oncogenic insults that profoundly impact OSE cells ([@R22], [@R21]), thereby explaining why granulosa cell tumors have not been observed in the previous studies ([@R11], [@R23], [@R47]).

Importantly, the low grade serous adenocarcinomas of the *Pten^fl/fl^;Kras^G12D^;Amhr2-Cre* mutant mice represent the first mouse model of this specific ovarian cancer subtype ([@R22]). The spontaneous and reproducible development of serous adenocarcinomas in these mice have lead us to determine what molecular pathways are altered in these cells and if this model can be used to understand the molecular events controlling the transformation of OSE cells and thereby provide some insights into this cancer subtype in women. In particular, this model, unlike other models, affords the opportunity to track the initiation of transformation of OSE cells at early stages *in vivo* by determining when the mutant OSE cells first exhibit altered morphology and functions and what signaling pathways are required to maintain transformation in the OSE cells in this context. The striking increases Mullerian cell markers in the OSE tumors indicate that these cells can differentiation into a Fallopian-like epithelium. In addition, the consistent increases in *Trp53* expression and its target microRNA, miR-34a-c indicate that altered activation of the PI3K and RAS pathways is tightly linked to regulation of TRP53 levels and presumably function in these cells.

Results {#S2}
=======

OSE cell tumors are evident in the *Pten^fl/fl^; Kras^G12D^;Amhr2-cre* mice as early as 5 weeks of age and express markers of human serous adenocarcinomas {#S3}
----------------------------------------------------------------------------------------------------------------------------------------------------------

Histological sections prepared from ovaries of control mice at 5 and 10 weeks of age show that the OSE cell layer is comprised on a single layer of meso-epithelial cells as reported by others ([@R2], [@R47]). These cells stain for the epithelial cell markers cytokeratin 8 ([@R22]) and for E-cadherin (CDH1) but not for vimentin ([Figure 1A](#F1){ref-type="fig"}). In contrast, the OSE layer present in ovaries of the *Pten^fl/fl^;Kras^G12D^;Amhr2-Cre* mice exhibits visible changes in morphology with obvious epithelial cell hyperplasia evident as early as 3 weeks of age in some ovaries and at 5 weeks in all ovaries. By 10 weeks of age, all mice exhibited low-grade serous, papillary-like adenocarcinomas as classified by expert pathologists ([Fig. 1A](#F1){ref-type="fig"}). Of note, the OSE tumor cells stain for cytokeratin 8 ([@R23]) and vimentin but not for E-cadherin ([Figure 1A](#F1){ref-type="fig"}) suggesting that the cells have undergone an epithelial to mesenchymal type of transformation ([@R41]). Furthermore, the OSE tumor cells do not stain for calretinin, a marker of mesotheliomas and do not exhibit atypic nuclear morphology observed in high-grade adenocarcinomas ([Supplemental Figure 1](#SD1){ref-type="supplementary-material"}). However, the tumor OSE cells do stain positive for estrogen receptor alpha (ESR1), providing additional evidence that these tumors represent low-grade adenocarcinomas ([Supplemental Figure 1](#SD1){ref-type="supplementary-material"}) ([@R61]).

To identify specific genes expressed in the tumor-bearing ovaries at 3 months of age, total RNA was extracted from ovaries of control (wild-type) and *Pten ^fl/fl^; Kras^G12D^;Amhr2-Cre* mice and submitted for Microarray Analyses. Table 1 lists the top 25 most highly up-regulated genes in the *Pten ^fl/fl^; Kras^G12D^;Amhr2-Cre* tumor-bearing ovaries (Supplementary Table S1). These include potential regulators of stem cells (*Angtpl7*) ([@R66]), markers of cancer cells (*Nov*, also known as *Ccn3* ([@R5]), *Mela* and *Ptgs2*) ([@R58]), specific cytokines (*Gkn1, Gnk2* ) and the acute phase factor (*Hp*) ([@R1]).

When we compared our microarray data derived from normal ovaries and tumor-bearing ovaries of *Pten ^fl/fl^; Kras^G12D^;Amhr2-Cre* mice with data sets derived from human cancer cell lines expressing mutant or wild-type KRAS, 213 genes exhibited significantly over-lapping mutant *Kras*-related expression patterns ([Figure 2 A and B](#F2){ref-type="fig"}) (Supplementary Table S2). Genes highly expressed in the human mutant *Kras* expressing cancer cells and the mouse ovary tumor samples include: Ptgs2, Mpzl2 (Eva1), Cldn3, Lcn2, Ccnd1, Adam8, Egfr, Btc, Podxl, Msln, Igfbp4 and *Dusp6*. These results indicate that the transformed mouse cells exhibit a mutant *Kras* signature similar to that observed in human cancer cell lines ([@R26]).

The data sets from our tumor-bearing ovaries also exhibit overlapping expression with data sets from human ovarian cancers (as compared to normal ovary): 330 genes in human serous tumors and 331 in the mucinous tumors ([Figure 2A and C](#F2){ref-type="fig"}) ([@R44]). Among the common genes are *Cp, Lcn2, Dmkn, Msln, Cldn3, Podxl, Esr1* and *Muc16* as well as specific Mullerian epithelial marker genes, *Wt1, Pax8, Hoxa9* and *Hoxa10.* Genes encoding matrix components were also observed ([@R7], [@R9], [@R18], Gava N, Clarke CL, *et al.*, 281, [@R27], [@R36], [@R37], [@R44], [@R55], [@R56])(Supplementary Table S3). That many of the genes in the mouse and human ovarian cancer samples are common to the cancer cell *Kras* signature indicates that activation of *Kras* pathway (by mutations or other mechanisms) may be an underlying common feature of transformed OSE and Mullerian cells. Because a high percentage human ovarian cancer samples are likely to be high-grade serous adenocarcinomas, these tumors may harbor defects not only in the function of TP53 but also changes in the MET-RAS signaling pathway ([@R13], [@R67]).

Real-time RT-PCR results using RNA prepared from control and the tumor-bearing ovaries confirmed the Microarray data, documented age-dependent changes in gene expression profiles and verified up-regulation of specific genes known to be expressed in human ovarian cancers ([Fig.1B](#F1){ref-type="fig"}). *Cp, Podxl* and *Ptgs2* were expressed at elevated levels by 5 weeks of age whereas *Cldn3, Dmkn, Krt8, Lcn2, Msln* and *Angptl* were elevated at 10 weeks*. Wt1, Pax8, Hoxa9* and *Hoxa10* were also elevated in the mouse tumor tissue at 10 weeks of age indicating that these cells had acquired specific characteristics of Mullerian (Fallopian tube/endometrial) epithelial cells. Expression of the *Trp53* (*p53*) was also elevated in the tumor cells providing further evidence that there are distinct temporal changes in gene expression patterns in the mutant OSE cells.

Most genes expressed at reduced levels in the tumor-bearing ovaries from the *Pten ^fl/fl^;Kras^G12D^;Amhr2-cre* mice compared to controls are oocyte (\*) or granulosa cell specific (Supplemental Table S4) and reflect the loss of oocytes and altered granulosa cell differentiation in the abnormal follicle structures (Supplemental Table S2) present in these ovaries ([@R21]).

Tumor-related genes are selectively expressed in ovarian surface epithelial cells {#S4}
---------------------------------------------------------------------------------

To determine which of the genes associated with the tumor-bearing ovary at 5 and 10 weeks of age were expressed specifically in purified OSE cells, we isolated OSE cells from ovaries of WT and *Pten ^fl/fl^; Kras^G12D^;Amhr2-Cre* mice. The WT and mutant OSE cells (cytokerain 8 positive) were removed from the epithelium by mild-trypsin digestion ([Fig.3A](#F3){ref-type="fig"}, upper panel). The highly purified OSE cells from WT ovaries appear morphologically homogeneous in culture as indicated by the characteristic cuboidal-cell shape ([Fig.3A](#F3){ref-type="fig"}, middle panel) and uniform immunolabeling of cytokeratin 8 and E-cadherin ([Fig.3A](#F3){ref-type="fig"}, lower panel) as would be predicted from their presence *in vivo* ([Fig. 1](#F1){ref-type="fig"} and [Fig.3A](#F3){ref-type="fig"}).

Several genes (*Cldn3, Dmkn, Msln, Lcn2*) were higher in the purified WT OSE cells compared to WT whole ovaries ([Fig. 3B](#F3){ref-type="fig"}), suggesting that these genes are specific markers of OSE cells and function in the non-transformed epithelium. Furthermore, the expression of *Wt1, Pax8, Hoxa9* and *Hox10*, specific markers of Mullerian-derived (Fallopian and endometrial) epithelia ([@R7], [@R35]) were induced in the mutant mouse OSE cells ([Figure 3B](#F3){ref-type="fig"}). These results document unequivocally that mouse OSE cells can acquire Mullerian duct markers during transformation by disrupting *Pten* and expressing mutant *Kras^G12D^*. Differential gene expression patterns in the mutant OSE cells were observed: some genes were elevated selectively in cells from 10 weeks (*Hoxa9, Dmkn, Lcn2* and *Podxl*) whereas others were elevated at 5 and 10 weeks (*Cp, Cldn3, Krt8, Msln, Ptgs2, Wt1*, and *Angptl7*). A striking increase in *Trp53* mRNA and protein were also observed in the mutant OSE cells compared to WT cells ([Fig. 3C](#F3){ref-type="fig"}).

OSE cells isolated from ovaries of the *Pten^fl/fl^; Kras^G12D^;Amhr2-Cre* mice are transformed {#S5}
-----------------------------------------------------------------------------------------------

When OSE cells were isolated from WT or *Pten ^fl/fl^;Kras^G12D^;Amhr2-Cre* mouse ovaries at 5 and 10 weeks and cultured for 2 days, the growth rate of the mutant cells far exceeded that of the WT cells (4A). The mutant, but not WT, OSE cells also generated stable cell lines. To further confirm that the mutant OSE cells were transformed, purified WT and mutant OSE cells were prepared and plated in soft agar. Mutant cells isolated from the *Pten ^fl/fl^;Kras^G12D^;Amhr2-Cre* mice at 5 and 10 weeks formed colonies within 2 weeks whereas the WT cells did not ([Figure 4B](#F4){ref-type="fig"}). Moreover, mutant OSE cells prepared at 10 weeks formed significantly more colonies than did cells collected at 5 weeks, providing additional evidence that temporal changes in the function of mutant OSE cells occur *in vivo* and are retained in culture ([Figure 4C](#F4){ref-type="fig"}). Additionally, when the purified *Pten ^fl/fl^;Kras^G12D^;Amhr2-Cre* OSE cells were injected into recipient mice *in vivo*, ectopic tumors positive for cytokeratin 8 developed rapidly (within 2 weeks) in the peritoneal cavity, at subcutaneous sites and under the kidney capsule where invasive activity into the kidney capsule was evident ([Figure 4D](#F4){ref-type="fig"}). Thus, these transformed cells are highly proliferative and possess invasive activity.

The PI3K/AKT signaling pathway and ERK1/2 impact in the functions of the mutant OSE cells {#S6}
-----------------------------------------------------------------------------------------

The disruption of *Pten* and expression of mutant KRAS^G12D^ are expected to increase the activity of the PI3K/AKT and RAS/MEK1/ERK1/2 pathways, respectively. However, there is also important cross-talk between these pathways and increasing evidence indicates that activation of the PI3K pathway is essential to maintain the growth promoting and transformation effects of KRAS ([@R45]), in part, by blocking negative feedback regulatory loops ([@R60]). Therefore, we determined if pharmacological disruption of either PI3K or MEK1/ERK1/2 activity would prevent colony formation and/or the expression of selected genes. As shown in [Figure 5A](#F5){ref-type="fig"}, AKT and ERK1/2 are phosphorylated and hence activated in OSE cells isolated from ovaries of tumor-bearing mice at 10 weeks of age and this was blocked by blocked by inhibitors of PI3K (LY294002) and MEK1 (U0126), respectively. PTEN was undetectable and *Foxo1* mRNA was markedly reduced in the mutant OSE cell (data not shown). When U0126 and/or LY294002 were added to the soft agar, they inhibited colony formation by approximately 70-90% ([Fig. 5B](#F5){ref-type="fig"}).

Loss of colony formation was associated with reduced expression of specific genes including *Cp, Ptgs2, Dmnk, Lcn2* and *Ptgs2* that were selectively down-regulated by inhibition of PI3K as well as *Ccnd1,Cldn3, Krt8, Podxl* and *W1t* that were reduced by either the PI3K/AKT or ERK1/2 signaling cascade inhibitors. *Angptl7* was increased selectively by the PI3K inhibitor whereas *Trp53* mRNA and protein were reduced equally by either LY294002 or UO126 ([Figure 5C and 5D](#F5){ref-type="fig"}). Thus, the PI3K/AKT and MEK/ERK1/2 pathways are required to drive and maintain transformation of the mutant OSE cells.

To further characterize the specific effects of disrupting the PI3K pathway or activating the RAS pathway, we isolated and cultured OSE cells obtained from ovaries of *Ptenfl/fl;Amhr2-Cre* and *Kras^G12D^;Amhr2-Cre* mice as well as from the *Pten ^fl/fl^;Kras^G12D^;Amhr2-Cre* mice and WT mice at 10 week of age. Cells from each genotype exhibited slightly different morphology ([Fig 6A](#F6){ref-type="fig"}) and only cells from the *Pten ^fl/fl^;Kras^G12D^;Amhr2-Cre* mice were transformed. Genes that were highly expressed in the OSE cells from the tumor (T) bearing ovaries of the *Pten ^fl/fl^;Kras^G12D^;Amhr2-Cre* mice compared to WT were also elevated in OSE cells from the *Ptenfl/fl;Amhr2-Cre* mice. These include *Podxl,* markers of Mullerian epithelium *(Wt1and Hoxa9), Trp53* and one of its target genes *Cdkn1a (p21)* as well as a marker of serous adenocarcinomas, *Cldn3*. These genes were less dramatically increased in the *Kras^G12D^;Amhr2-Cre* mice indicating that disrupting the PI3K pathway alone exerts the more potent response in this context ([Fig 6B](#F6){ref-type="fig"}).

Specific microRNAs are regulated in the mutant OSE cells compared to WT OSE cells {#S7}
---------------------------------------------------------------------------------

MicroRNAs comprise an extensive class of non-coding nucleic acids that govern broad gene regulatory pathways in development ([@R57]). Specific microRNAs presumed to be linked to various cancers, including ovarian cancer, have been identified ([@R15], [@R17], [@R29], [@R38], [@R46], [@R63], [@R65]). Those highlighted most frequently are members of the *Let-7* cluster that regulate (K/H)RAS and *Hmga2*, a potent regulator of proliferation ([@R52]), *miR-21* that is transcriptionally controlled by STAT3, AP1 factors and/or TRP53 ([@R38]) and regulates such diverse processes as cell proliferation, invasion and migration ([@R38]), *miR-34a/c* that are targets of TRP53 and potent inhibitors of the cell growth regulators ([@R28], [@R31]), *miR-29a* that is a target of WNT/CTNNB1 ([@R32]) and regulates *Trp53* ([@R49]), *miR-125b* that may target RAS ([@R53]) and *miR-214* that impacts the level of mRNA encoding the tumor suppressor *Pten* ([@R65]).

Based on these studies, we analyzed several microRNAs in our WT and mutant OSE cells in culture ([Fig 7A](#F7){ref-type="fig"}). We show that primary transcripts of *Let-7f* and miR-21, miR-29a, miR-34a, miR-34c, miR-125b-5p, miR-199a-5p, miR-720 and *miR-1937* were increased dramatically in the mutant cells isolated from tumors of mice at 5 and 10 weeks of age compared to WT cells whereas *miR-31* was dramatically reduced. These results indicate that transcription of these microRNAs is being regulated in the mutant mouse OSE cells. The expression of the mature forms of these microRNAs was verified for *Let-7f* and *miR-34a* ([Fig 7B](#F7){ref-type="fig"}). With the exception of *miR-31*, the expression of these microRNAs is regulated by inhibitors of PI3K (LY294002) or MEK1/ERK1/2 (U0126). Of particular interest is the down-regulation of *miR-21, miR-29a, miR-34c, miR125b-5p*, and *miR-720* in response to U0126 indicating that ERK1/2 is a potent regulator of these microRNAs. Other microRNAs (*miR-29a, miR-199a-5p*, and *miR-1937*) were potently down-regulated by both inhibitors. Additionally, *miR-34a*, like *Trp53*, was increased in cells lacking *Pten* alone, whereas *miR-31* was selectively suppressed in cells expressing *Kras^G12D^* but not those lacking *Pten* indicating that each pathway controls the expression of distinct miRNAs presumed involved in transformation.

Discussion {#S8}
==========

These studies document that the *Pten ^fl/fl^;Kras^G12D^;Amhr2-Cre* mice develop low-grade serous-type adenocarcinomas with 100% penetrance and at an early age. Detailed analyses of purified OSE cells obtained from the mutant mice provide unequivocal evidence that the cells are transformed, grow in soft agar and form ectopic invasive tumors when injected into recipient mice. That the tumors of *Pten ^fl/fl^;Kras^G12D^;Amhr2-Cre* mice are the first to recapitulate diagnostic aspects of the human low-grade serous sub-type ([@R44], [@R56]) is supported by several observations. Comparisons of microarray databases show highly significant overlap in genes expressed in the mouse and human tumor cells. Importantly, the *Kras/Pten* mutant cells but not WT OSE cells express *Wt1*, *Hoxa9, Hox10* and *Pax8* genes that are characteristic markers of Fallopian/Mullerian epithelia ([@R39]). The expression of *Hoxa9* is of particular interest because it is not only important for normal tissue development but is highly expressed in other cancer cell types, including leukemias ([@R59]) and astrocytomas ([@R14]) where it is thought to maintain the survival of progenitor cells and to be regulated by PI3K ([@R14]). Other genes that are up-regulated in the mutant mouse OSE cells are similar to ones that are enhanced in human ovarian serous adenocarcinomas ([@R9], [@R18], Gava N, Clarke CL, *et al.*, 281, [@R27], [@R36], [@R37], [@R44], [@R55], [@R56]). These include *Cldn3* and *Msln* that are increased preferentially in serous adenocarcinomas expressing *Hoxa9* ([@R7]). Thus, although recent evidence suggests that some ovarian cancers, especially high-grade serous adenocarcinomas, may be derived from mutant Fallopian tube or endometrial epithelial cells that migrate to the ovarian surface ([@R16], [@R20], [@R33], [@R39], [@R42], [@R51]), our results and those of others ([@R11], [@R19], [@R24], [@R47], [@R62]) document that mouse OSE cells can transform if exposed to specific oncogenic insults and that they may have some characteristics of multi-potent cells ([@R6]) ([@R3]).

Many microRNAs expressed in the mutant mouse OSE tumor cells are also present in human ovarian cancer. Of particular relevance are members of the *Let-7* cluster ([@R52]) that regulate *Kras*, *miR-21* ([@R38]) that is regulated by *Kras*, *miR-34a/c* that are transcriptional targets of TRP53 and potent inhibitors of the cell growth and therefore appear to act as tumor suppressors ([@R28], [@R31]), *miR-29a* ([@R32]) that regulates *Trp53* ([@R49]), *miR-125b* that may target RAS ([@R53]) and *miR-214* that impacts the level of mRNA encoding the tumor suppressor *Pten* ([@R65]). That these miRNAs have been detected in various human ovarian cancer samples underscores their potential regulatory roles in the initiation and/or maintenance of the transformed phenotype. That many miRNAs were highest in mutant OSE cells isolated from ovaries of mice at 5 weeks indicates that the molecular activities as well as the growth rate of the mutant OSE cells change with time and tumor growth.

The molecular basis of the different histological phenotypes of ovarian cancer subtypes remains puzzling. For example, the serous adenocarcinomas of the *Pten ^fl/fl^;Kras^G12D^;Amhr2-Cre* mice described herein ([@R22]) differ in their histological architecture from the endometrioid-like OSE tumors in the mice reported by Dinulescu *et al* ([@R19]). Although the same mutant *Pten* and *Kras^G12D^* mouse strains were used, the tumors in each model were generated by different approaches and in OSE cells at different stages of differentiation. In our model OSE cells are transformed by endogenous *Amhr-2Cre* expressed directly in these cells *in vivo* and in mice prior to puberty; hence prior to increases in ovarian steroid production. Conversely, the *Kras* and *Pten* mutations in the Dinulescu model were generated by adenoviral Cre injections into the ovarian bursa of mice primed with gonadotropin ([@R19]) and therefore have been exposed to steroids. Because phenotypic outcome in each model appears to be highly reproducible, one plausible explanation for the distinct histological features is that the stage of OSE cell differentiation when they are exposed to the oncogenes determines the response.

Impressively, many genes selectively expressed in the *Pten ^fl/fl^; Kras^G12D^;Amhr2-Cre* mouse tumor cells as well as in serous and mucinous human tumors share a common "*Kras* signature" observed in other cancer cell types ([Figure 2](#F2){ref-type="fig"}), suggesting that activation of *Kras* pathway, by mutation or other mechanisms provide a mechanism that yields a common transformed outcome. Although a "*Pten* signature" was not significant, selective activation of the PI3K pathway by loss of *Pten* in OSE cell of the *Pten ^fl/fl^;Amhr2-Cre* mice leads to specific and marked changes in mRNA and miRNA profiles in the OSE cells. Of note, *Trp53, Cdkna1, Cldn3* and *miR-34a* are increased suggesting that components of the *Trp53* pathway are key targets of the PI3K pathway. Conversely, *Trp53, miR-34a* and *miR-31* are expressed but at lower levels in the tumor cells of *Pten ^fl/fl^; Kras^G12D^;Amhr2-Cre* mice and OSE cells of *Kras^G12D^;Amhr2-Cre* mice indicating that activation of the KRAS pathway alters the effects of the PI3K pathway.

Moreover, when inhibitors of the PI3K and RAS pathways were added in culture to OSE cells already transformed, they blocked mutant OSE cell growth in soft agar and selectively altered the expression of key marker genes, indicating that both pathways are critical to maintain the transformed phenotype. Because the inhibition of PI3K was more effective than inhibition of MEK1/ERK1/2 on cell growth indicates that the PI3K pathway may be a more potent driver of proliferation, perhaps involving the regulatory effects of *Hoxa9* and *Meis1* ([@R14]). However, the observed potency of PI3K may also be related to the ability of PI3K to activate the RAS/MEK1/ERK1/2 pathway, thereby, stimulating both signaling cascades. Conversely, the lesser effects of U0126 indicate that blocking MEK1 and ERK1/2 disrupts only one arm of the RAS signaling cascade but will not block the affects of KRAS on PI3K or other pathways in these cells ([@R60]). Thus, the critical role of KRAS is underscored most impressively by the extensive number of human mutant *Kras* target genes (\~213) that are also expressed in the murine and human OSE tumors cells ([Figure 2](#F2){ref-type="fig"}). Collectively, these results provide strong evidence that the *Pten ^fl/fl^;Kras^G12D^;Amhr2-Cre* mouse model is relevant to a subset of the human ovarian cancers and for determining the molecular events by which these two oncogenic pathways intersect to initiate transformation and also control the TRP53 pathway.

More aggressive ovarian cancer is associated with frequent mutations or deletions of TRP53 ([@R9]). Strikingly, the mutant OSE cells from the *Pten ^fl/fl^;Kras^G12D^;Amhr2-Cre* mice as well as in the *Pten ^fl/fl^;Amhr2-Cre* mice express increased levels of *Trp53* mRNA and protein. As a potent tumor suppressor ([@R11], [@R24], [@R47]), TRP53 may exert negative regulatory effects in the mutant *Pten ^fl/fl^;Amhr2-Cre* and *Pten ^fl/fl^;Kras^G12D^;Amhr2-Cre* cells to prevent more aggressive proliferation and metastatic activity (Astanehe A, Arenillas D *et al*., 2008). TRP53 appears to be active in the mutant cells because known targets are elevated selectively in the mutant OSE cells, including microRNAs, *miR34a* and *miR34c*, that have also been shown to exhibit tumor suppressor activity, genes encoding regulators of cell proliferation such as p21^CIP^ ([@R12], [@R13], [@R28]) and CCN3 that regulates cell adhesion ([@R5]). Thus, TRP53 and miR-34a in mouse and human low-grade adenocarcinomas may serve as an underlying negative molecular regulatory network that controls the low-grade tumorgenicity and perhaps cytotoxic resistance of these cells.

In summary, murine OSE cells respond to known oncogenic insults, *Pten* deletion and *Kras* activation (*Kras^G12D^*), and undergo transformation, leading to the formation of low-grade serous adenocarcinomas spontaneously *in vivo*. The mutant mouse OSE cells acquire morphological and biochemical characteristics of Mullerian derived epithelial cells. Moreover, these "differentiated" transformed cells express specific mRNA and miRNAs known to be expressed in human ovarian cancers indicating that this mouse model has relevance for understanding the specific effects of these two oncogenic factors in this cellular context and their interactions alone and together on the TRP53 pathway.

Materials and Methods {#S9}
=====================

Animal procedures {#S10}
-----------------

LSL-Kras^G12D^;Amhr2-Cre, Pten^fl/fl^;Amhr2-Cre; LSL-Kras^G12D^;Pten^fl/fl^;Amhr2-Cre, mice were derived and genotyped as previously described ([@R22], [@R21]). *Trp53^fl/fl^;Amhr2-cre* mice were derived from previously described *Amhr2-Cre* and *Trp53^fl/fl^* mice (obtained from the Mouse Models of Human Cancer Consortium, MMHCC, NCI-Frederick, MD ([@R50]). Animals were housed under a 16-h light/8-h dark schedule in the Center for Comparative Medicine at Baylor College of Medicine and provided food and water *ad libitum*. Animals were treated in accordance with the NIH Guide for the Care and Use of Laboratory Animals, as approved by the Animal care and Use Committee at the Baylor College of Medicine.

Histology and Immunohistochemistry {#S11}
----------------------------------

Ovaries were collected and fixed in 4% parformaldehyde, embedded in paraffin and processed by routine procedures for immunohistochemisrty ([@R22]) of Cytokeratin 8 (ab59400 Abcam, Cambridge, MA).

Immunofluorescence {#S12}
------------------

Ovaries were fixed in 4% parformaldehyde, embedded in optimal cutting temperature (OCT) compound (Sakura Finetek Inc., USA) and stored at -70° C. 7uM sections were immunostained ([@R23]) with antibodies against: cytokeratin 8 (as above), E-cadherin (24E10), Vimentin (R28) from Cell Signaling (Danvers, MA) and TRP53 (p53) (Sc-6243) from Santa Cruz Biotechnology (Santa Cruz, CA).

Western blots {#S13}
-------------

Whole cell extracts were prepared by lysing ovaries in radioimmunoprecipitation assay (RIPA) buffer containing protease inhibitors (Roche, Nutley, NJ). Western blot analyses was performed using 30ug of lysate protein for each sample. Cell extracts were prepared from cultured OSE cells by lysis 1X sodium dodecyl sulfate (SDS) sample buffer at 100F for 5 min and 35 ul of each sample analyzed by Western blot using antibodies, AKT and phospho-AKT (9272, 4058L), and ERK and phospho-ERK (9102, 9101S) from Cell Signaling (Danvers, MA) and TRP53 (p53) (Sc-6243) from Santa Cruz Biotechnology (Santa Cruz, CA).

Isolation and culture of primary OSE cells {#S14}
------------------------------------------

Ovaries were harvested from mice of indicated ages and gently washed once with serum free DMEM-F12 media. The OSE cells were released by mild-trypsin digestion ([@R24]) with modifications. The ovaries from 1-5 mice were then placed in a 15 ml conical tube containing 5 mls of room temperature (20-24 °C) buffer (0.25% w/v trypsin --EDTA)( Gibco/Invitrogen, Carlsbad, CA) for 30 minutes in a 37° incubator with 5%CO~2~. After 30 minutes the tube was gently tipped back and forth 10 times and the supernatant containing the OSE cells was transferred to a new tube and the cells collected by centrifugation at 1,000xg for 10 minutes. The cells from each tube were resuspended in DMEM-F12 growth media (10% FBS, 5% Insulin-Transferrin-selenium-A \[Gibco/Invitrogen, Carlsbad, CA\]) and 5% Penicillin-Streptomycin \[Gibco/Invitrogen, Carlsbad, CA\]) and plated in separate wells of a 24-well tissue culture plate. Fresh media was added every 2-3 days and the cells harvested when 90-100% confluent (7-10 days).

Innoculation of cells into mice {#S15}
-------------------------------

100,000 cultured OSE cells isolated from a 10 week *Pten^fl/fl^;Kras^G12D^;Amhr2-Cre* mouse were grafted along with collagen under the renal capsule of wild type mice with the same genetic background. 100,000 cells were also injected subcutaneously along with Matrigel (BC Biosciences) according to the manufacturer\'s protocol. In addition, mice were injected itraperitoneally with 100,000 cells. Tumors were harvested and fixed in 4% paraformaldehyde after 20 days.

Real time RT-PCR for mRNAs, primary(pri)-miRNAs and mature miRNAs {#S16}
-----------------------------------------------------------------

Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Germantown, MD) and treated with DNase I (DNA-free™, Ambion) according to the manufacturer\'s instructions. cDNA was synthesized with a Taqman reverse transcriptase reagent kit (Applied Biosystems, Foster City, CA) primed with random hexamers. Real-time PCR was performed using the Light Cycler DNA Master SYBR Green I kit (Roche Applied Sciences, Nutley, NJ). Primers (Supplementary Table S5) were used at a concentration of 0.5 μM and MgCl~2~ at 2.4 mM. Samples were denatured for 10 min at 95 °C and then 40 cycles of 95 °C for 20 s, 60 °C for 20 s and 72 °C for 20s as previously([@R22]). Data were normalized to L19 using the comparative *C~t~* method. Data are presented as the mean +/- SEM of a representative of at least 3 experiments performed in triplicate.

Small RNAs required for detecting and measuring mature miRNAs were extracted using the mirVANA miRNA Isolation Kit (Ambion, Inc. Austin, TX) according to manufacturer\'s instructions. Reverse transcription was performed as described above. For quantification of mature miRNAs, the TaqMan MicroRNA assay kit (Applied Biosystems, Foster City, CA) was used according to the manufacturer\'s instructions.

Microarray {#S17}
----------

Total RNA was prepared using the RNeasy Mini Kit (Qiagen, Germantown, MD from ovaries of control and *Pten^fl/fl^;Kras^G12D^;Amhr2-cre* mice at 3 months of age when ovaries of the mutant mice contained a substantial amount of tumor. The quality of the RNA was verified in the MicroArray Core Facility at Baylor College of Medicine and hybridized in duplicate to Mouse 420.3 Affymetrix Chips using routine procedures.

Gene Expression Analysis {#S18}
------------------------

After scanning and low-level quantification using Microarray Suite (Affymetrix), DNA Chip (dChip) analyzer ([www.dchip.org](http://www.dchip.org)) was used to estimate expression values. Fold changes between control and *Pten^fl/fl^;Kras^G12D^;Amhr2-cre* mice were estimated, using the ratio of expression values. Expression profiles of human cell lines were obtained from Glaxo ([@R26]) and expression profiles of human ovarian tumors and normal ovary were obtained from GEO (GSE6008). Two-sided t-tests using log-transformed data determined significant differences in mean gene mRNA levels between sample groups. The mapping of transcripts or genes between the mouse signature and the human tumor array datasets was made on the Entrez Gene identifier (using the human orthologs from the mouse dataset); where multiple human array probe sets referenced the same gene, the probe set with the highest variation was used to represent the gene. One-sided Fisher\'s exact tests determined the significance of overlap between the mouse and human gene sets (using the 15092 unique human gene orthologs represented on the mouse array as the population). Expression patterns were visualized as color maps using the JavaTree Software ([@R54]).
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![Temporal changes in OSE cell morphology and expression of specific genes associated with the serous adenocarcinoma phenotype in the *Pten;Kras^G12D^;Amhr2-cre* mice. A.) H&E and immuno-labeling of ovarian sections from WT and mutant mice at 5 and 10 weeks of age. B.) Gene expression patterns in whole ovaries of WT or tumor bearing (T) *Pten;Kras^G12D^;Amhr2-cre* mice at 5 and 10 weeks of age.](nihms-262048-f0001){#F1}

![Genes overlapping between the *Pten;Kras;Amhr2-cre* gene signature and relevant signatures from human cancers. (A) Overlaps between the set of human orthologs high (fold\>2) in *Pten;Kras;Amhr2-cre* mice (compared to wild-type mice) and various sets of genes derived from human datasets: genes high/low (p\<0.01, t-test) in k-ras mutant versus k-ras wild-type cell lines, and genes high/low (p\<0.05) in serous, mucinous, or endometrioid ovarian cancers, as compared to normal ovary. Numbers of genes in each set indicated in parentheses. Numbers overlapping between sets were compared to chance expected. (B) Heat maps showing expression patterns for the *Pten;Kras;Amhr2-cre* gene signature, both in the *Pten;Kras;Amhr2-cre* mouse expression dataset and in an expression dataset of human cancer cell lines with or without mutations in kras (35). (C) Heat maps for the *Pten;Kras;Amhr2-cre* gene signature, both in the mouse dataset and in a dataset of human ovarian tumors (36). For parts B and C, genes represented in both heat maps are the same and have the same ordering, and genes not represented in the given human dataset are not shown.](nihms-262048-f0002){#F2}

![Mutant OSE cells express genes associated with human serous adenocarcinomas in a time-dependent manner. A.) Cytokeratin 8 and E-cadherin-positive OSE cells removed from the ovarian surface exhibit a cobblestone appearance. B.) Expression of genes in RNA samples from whole ovaries and purified OSE cells isolated from ovaries of wild type and *Pten;Kras^G12D^;Amhr2-cre* mice at 5 and 10 weeks of age.](nihms-262048-f0003){#F3}

![OSE cells isolated from ovaries of *Pten;Kras;Amhr2-cre* mice are transformed. A.) Mutant OSE cells proliferate faster than WT cells at 24 and 48h. B.) Mutant but not WT OSE cells grow in soft agar (C) and form ectopic tumors in the peritoneal cavity, subcutaneously and under the kidney capsule *in vivo* (D).](nihms-262048-f0004){#F4}

![The MEK1/ERK1/2 and PI3K/AKT pathways drive gene expression and transformation of the mutant OSE cells. A.) Western blot of lysates prepared from mutant OSE cells cultured in media alone or with either the MEK1 inhibitor UO126 (10 □M) or the PI3K inhibitor LY294002 (10 □M) for 24 hrs. B.) Colony formation of mutant OSE cells grown in soft agar is inhibited by both UO126 and LY294002. C.) Gene expression is altered in cells cultured in media alone or with either UO126 or LY294002 for 24h. D.) TRP53 immunolabeling decreases in mutant cells cultured for 24 hours with or without 10 □M UO126 or LY294002 compared to media alone.](nihms-262048-f0005){#F5}

![Mutations in either *Pten* or *Kras* alone alter gene expression in purified OSE cells. A.) OSE cells were isolated from Pten;Amhr2-cre, Kras;Amhr2-cre, Pten;Kras;Amhr2-cre (tumor-bearing, T) and WT mice. The transformed cells (T) grow rapidly and eventually form clusters whereas the WT and KRAS OSE cells exhibit slower growth and well-defined boarders. OSE cells from the *Pten* null cells, like the transformed (T) cells, lack distinct borders but are not transformed. B.) The transformed cells and the *Pten* null cells exhibit striking similarities in the expression of specific mRNAs, including Trp53 and its target p21 (Cdkna1).](nihms-262048-f0006){#F6}

![Specific miRNAs are expressed in the mutant compared to WT OSE cells and are regulated by inhibitors of MEK1/ERK1/2 and PI3K as shown by real-time RT-PCR. A and B.) [Primary]{.ul} miRNA and [mature]{.ul} transcripts are transcriptionally regulated in mutant OSE cells at 5 and 10 weeks of age. C.) Transcription of [primary]{.ul} miRNAs is altered by UO126 or LY294002. D.) miR-34a is elevated in OSE cells from *Pten;Kras;Amhr2-cre* (tumor-bearing, T) mice and from *Pten;Kras;Amhr2-cre* mice (Pten) but not from *Kras;Amhr2-cre* mice (Kras). Conversely, the potential tumor suppressor miR-31 is down-regulated in the tumor OSE cells and Kras cells but not the Pten null cells, indicating differential regulation of these two pathways.](nihms-262048-f0007){#F7}
